奥希替尼联合度伐利尤单抗对比奥希替尼单药治疗既往EGFR-TKI治疗后EGFR T790M阳性NSCLC:CAURAL简报
CAURAL是一项III期开放标签随机试验,比较奥希替尼联合度伐利尤单抗与奥希替尼单药在既往EGFR-TKI治疗后进展的EGFR T790M阳性晚期NSCLC患者中的安全性和疗效。因TATTON试验中联合组间质性肺病样事件增加,CAURAL提前终止招募,最终奥希替尼组15例、联合组14例。联合组客观缓解率64%,奥希替尼组80%;患者数有限无法进行正式比较。
要点
- CAURAL因TATTON试验中联合组间质性肺病样事件增加而提前终止招募。
- 奥希替尼组最常见不良事件为腹泻(53%,≥3级6%),联合组为皮疹(67%,≥3级0例)。
- 客观缓解率奥希替尼组80%,联合组64%;患者数有限无法正式比较安全性和疗效。
核心结论
- 有限的患者数量无法对两个治疗组进行正式的安全性和疗效比较。
- 程序性细胞死亡1/程序性细胞死亡配体1抑制剂与EGFR-TKI联合治疗NSCLC的机制尚不明确,未来若考虑需谨慎对待。
研究设计与样本
- III期开放标签CAURAL试验(NCT02454933),患者按1:1随机接受口服奥希替尼80 mg每日一次联合或不联合静脉度伐利尤单抗10 mg/kg每2周一次,直至进展。
- 招募因TATTON试验(NCT02143466)中奥希替尼联合度伐利尤单抗组间质性肺病样事件发生率增加而提前终止,终止时奥希替尼组15例、联合组14例。
- 修正后的主要目标为评估奥希替尼联合度伐利尤单抗的安全性和耐受性,疗效为探索性目标;疾病进展后若研究者判断临床获益持续可继续治疗。
主要发现
- 奥希替尼组最常见不良事件为腹泻(53%,≥3级6%),联合组为皮疹(67%,≥3级0例)。
- 一例随机至联合组的患者在接受奥希替尼单药治疗期间(停用度伐利尤单抗一剂后)报告2级间质性肺病。
- 客观缓解率奥希替尼组80%,联合组64%。
临床怎么用
- 原文未据此给出推荐。
局限性
- CAURAL招募因TATTON试验中奥希替尼联合度伐利尤单抗组间质性肺病样事件发生率增加而提前终止。
- 有限的患者数量无法对两个治疗组进行正式的安全性和疗效比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). Durvalumab is an anti-programmed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation-positive advanced NSCLC and disease progression after EGFR-TKI therapy. METHODS: Patients were randomly assigned 1:1 to receive orally administered osimertinib (80 mg once daily) with or without durvalumab (10 mg/kg administered intravenously every 2 weeks) until progression. Treatment could continue beyond progression, providing clinical benefit continued (judged by the investigator). The amended primary objective was to assess the safety and tolerability of osimertinib plus durvalumab; efficacy was an exploratory objective. RESULTS: CAURAL recruitment was terminated early because of increased incidence of interstitial lung disease-like events in the osimertinib plus durvalumab arm from the separate phase Ib TATTON trial (NCT02143466). At termination of CAURAL recruitment, 15 patients had been randomly assigned to treatment with osimertinib and 14 to treatment with osimertinib plus durvalumab. The most common AEs were diarrhea (53% [grade ≥3 in 6% of patients]) in the osimertinib arm and rash (67% [grade ≥3 in 0 patients]) in the combination arm. One patient who had been randomized to the combination arm reported grade 2 interstitial lung disease while receiving osimertinib monotherapy (after discontinuing durvalumab therapy after one dose). The objective response rates were 80% in the osimertinib arm and 64% in the combination arm. CONCLUSION: Limited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms. The combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR-TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.
引用
- Yang JC, Shepherd FA, Kim DW, et al. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019. PMID: 30763730. doi:10.1016/j.jtho.2019.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。